title: Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis.
abstract: BACKGROUND
  The diagnosis of malignant lymphoma (ML) such as non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) was mainly performed by morphological examination and gene analysis. There are only a few serum/plasma biomarkers such as lactate dehydrogenase and soluble interleukin-2 receptor alpha to diagnose ML. The classifications are various, and therefore the cell surface markers using flow cytometry or lymph node biopsy have been examined. It is difficult, however, to distinguish the two diseases, NHL and HL, from each other.
  
  
  METHODS
  In order to identify the haematological malignancy-associated autoimmunoreactivity (autoantibodies) in patients' plasma, a novel proteomics-based approach using electrophoresis/mass spectrometry was applied. Solubilized proteins from a Burkitt's lymphoma cell line (Raji) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis, in which the plasma of individual patients with haematological malignancies was tested for primary antibodies, followed by visualization with anti-IgG antibody conjugated with horseradish peroxidase.
  
  
  RESULTS
  Two proteins, L-plastin and alpha-enolase, capable of reacting with the antibodies in plasma of patients with NHL, were detected using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry and tandem mass spectrometry. The rates of the detections of an anti L-plastin autoantibody were significantly higher: 0.84 (21/25) in patients with NHL; 0.00 (0/4) in HL; 0.38 (5/13) in autoimmune diseases; 0.20 (2/10) in leukaemia; and 0.13 (1/8) in healthy controls. In contrast, those of anti alpha-enolase antibody were not specific to NHL.
  
  
  CONCLUSIONS
  We first identified autoantibody against L-plastin in plasma of patients with NHL, suggesting that the autoantibody can be a new diagnostic biomarker for NHL.
authors.affiliation: Central Clinical Laboratory, Osaka Medical College Hospital, 2-7 Daigaku-cho, Takatsuki City, Osaka, Japan.
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Ueda
authors.forename: Toyofumi
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Akira
authors.initials: A
authors.lastname: Shimizu
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takubo
authors.forename: Nariaki
authors.initials: N
authors.lastname: Matsuura
mesh_terms: D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000276:immunology*; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D010750:Phosphoproteins / Q000276:immunology*; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D001323:Autoantibodies; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D010750:Phosphoproteins; C026742:plastin